

# Laboratorios Rubió 2021

**Corporate Presentation** 



# We are pharmacy pathfinders

Making a dream come true is a big thing, but helping others to get it done is even better. To achieve this, there is a way of being that characterizes us and also moves us.

That's why we like to call ourselves: **Pharmacy Pathfinders** 

#### And what is it?

In being where the patient is, regardless of its prevalence, providing solutions. A way of being our own, because we are : **Pharmacy Pathfinders** 










## Our origins

A private company, founded in 1968 by the brothers Pelayo and Salvador Rubió. Currently under the direction of the second generation, Carlos and Pelayo Rubió, the sons of the founders. The company began in a family pharmacy, located in Barcelona's Plaza Real, preparing compound formulas to meet the needs of doctors treating patients who suffered from uncommon diseases.

Some of these products are currently chosen as a first treatment option, still having a leading position over new drugs in both terms efficacy and safety, conforming the basis of the company's international strategy.





### Values

## We are committed to provide:

- Service to people who suffer from diseases of low prevalence/incidence.
- Innovative products to specialists to aid in the treatment management of their patients.

We are a solid-established specialist pharmaceutical company that is strengthening its presence in Spain and increasing its international activity:

- By a complete development of its current portfolio of products.
- By seeking out business opportunities with a high level of added value.
- By focusing our efforts on specific therapeutic areas.
- By having a focus mid and long term strategy.
- By having a professional team that is swift to make decisions.



## Therapeutic Areas

#### **Primary Areas**

57

Rheumatology, Nephrology/Urology, Central Nervous System, Cardiovascular risk and Atherosclerosis and Nutrition with Food for Special Medical Purposes (FSMP)

#### **Secondary Areas**

Oncology, Radiotherapy and Gynecology

#### Strategy

The strategic goal of the company is to focus on key therapeutic areas to provide **"global therapy options for the patients"**, encompassing a broad range of products, including medicines, medical devices, and diagnostic tests.

# 2

One of the axis for the growth of the company is the development of its exportation business, which was begun in 1982.

Current international business represents **more than 50%** of the total number of the company's manufactured units, invested in expansion projects in new and existing markets, such as France, Scandinavia and the United States.

## 3

Research, both in terms of the development of new medicines as well improving our own formulations, plays a fundamental role in Rubió's strategy.

Furthermore, so are the agreements with **Research Centres** of excellence for the development of cutting edge technology projects which serve to supplement our current work.

#### Strategy

# 4

Rubió is at the **forefront in the treatment of Attention Deficit Hyperactivity Disorder** (ADHD) and our presence is significant in the fields of rheumatoid arthritis, lupus and chronic kidney disease.

# 5

In 2014, Rubió managed the expansion of the company. It acquired a percentage share in a newly created company called Biosfer Teslab and obtained the exclusive marketing rights for Liposcale<sup>®</sup>.

It is an advanced lipoprotein test based on 2D nuclear magnetic resonance (NMR).

## 6

Lisposcale<sup>®</sup> the advanced test based on NMR spectroscopy state of the art technology, used to identify people with liporotein-related cardiovascular events. It has proven to be more accurate for the determination of lipoproteins than any of the alternatives currently available on the market. And 2018 Rubio started a new division focus on development of Food for **Especial Medical Purposes (FSMPs)** 

# Production centre

Rubió has its own modern production plant with capacity to prepare more than 10 million units of finished product each year. This centre, with an area of 2,900 square metres, is equipped with cutting edge technology for the preparation of oral solid dosage forms.

At these facilities are also located the laboratories for quality control and development of pharmaceutical formulation techniques.





## Business in Spain

#### **Commercial Network**

Rubió's sales force in Spain is compounded of two teams:

#### **Rx Business Unit:**

- 29 Sales Representatives who visit specialist doctors
- 2 Territory Sales Managers
- 1 Marketing Manager
- 4 Therapeutic Area Managers
- 1 Ftes BD Manager
- 1 Fte Business Intelligence Manager
- 1 Business Unit Director

#### Dx and Hospital Products B.U.:

- 4 Hospital Key account Mangers
- 1 Brand Manager
- 1 Medical Advisor
  - 1 Business Unit Director




## International Business

Commercial strategy

### Presence in more than 60 countries,

through distributors or laboratories with product license.

The international portfolio strategy is built around the company's internally-produced strategic products: **Rubifen** (methylphenidate), **Resincalcio/Resinsodio** (calcium/sodium polystyrene sulfonate) and **Resincolestiramina** (cholestyramine). The international sales plan anticipates the marketing of our products though select specialist laboratories in each country that guarantee us the best entry into the market by sharing our knowledge and broad experience.





#### **Countries where currently a sales relationship exists (60 countries)**

Albania, Algeria, Andorra, Argentina, Canada, Chile, Colombia, Costa Rica, Croatia, Cuba, Cyprus, Denmark, Dominican Republic, Egypt, El Salvador, Finland, France, Georgia, Germany, Greece, Guatemala, Guinea, Honduras, Hong Kong, Hungary, Iran, Iraq, Israel, Kosovo, Lebanon, Lithuania, Malaysia, Malta, Mauritius, Mexico, Morocco, Netherlands, New Zealand, Nicaragua, Norway, Pakistan, Panama, Portugal, Romania, Saudi Arabia, Serbia, Singapore, Slovenia, South Africa, Sri Lanka, Sudan, Suriname, Sweden, Thailand, The Philippines, Tunisia, UAE, UK, Uruguay, US, Vietnam

**Countries where licensing/distribution agreements are currently in the registration phase (4 countries)** Australia, China, Estonia, Kuwait



With the creation of Products & Technology, in 2014, Rubió decisively boosted the area of R&D+i, **turning focus towards innovation** in order to develop new medicines and improve its own formulations.

Within this area, the strategy is based on expanding the lifecycle of their own products, collaborating in new research programmes, and establishing strategic alliances.

